InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Planned Strategy for Achieving Commercial Scale, Updated Release on 1-for-40 Reverse Split

Aditxt (NASDAQ: ADTX), a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system, announced an important update regarding its innovation programs and strategic M&A initiatives. The shareholder update provides the company’s planned strategy for achieving commercial scale. “Aditxt takes a stakeholder-driven approach to developing and deploying some of the most promising health innovations such as Pearsanta’s immune monitoring platform and Adimune’s immune modulation therapeutic,” Amro Albanna, Aditxt CEO, chairman and co-founder states in the update. “Our goal is to get our current programs to reach key clinical or commercial stage and expand our portfolio of innovations to address additional markets such as oncology and neurology.”

The company also issued a correction and replacement of its Aug. 17 announcement of a 1-for-40 reverse stock split. According to the update, the “First paragraph, first sentence of release should read: Aditxt, Inc. (NASDAQ: ADTX) (‘Aditxt’ or the ‘Company’), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, announced today that it will effect a 1-for-40 reverse split of its common stock…”

To view the full press releases, visit https://ibn.fm/51gvr and https://ibn.fm/fQzl0

About Aditxt Inc.

Aditxt is a global innovation company focused on innovation and activation of precision medicine therapeutics and technologies that monitor and modulate the immune system. Headquartered in Richmond, Virginia, the company has operations in Silicon Valley, California, and New York, New York. Aditxt’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire its mission. Aditxt’s diverse innovation portfolio includes: Adimune(TM), developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir(TM), focused on identifying, developing, and commercializing new ways to treat infectious diseases; and Pearsanta(TM), which offers personalized immune monitoring for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy. For more information, visit the company’s websites at www.Aditxt.com, www.Adimune.com and www.Pearsanta.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.